ERAS

ERAS

USD

Erasca Inc. Common Stock

$1.520-0.060 (-3.797%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$1.580

Haut

$1.615

Bas

$1.515

Volume

1.46M

Fondamentaux de l'Entreprise

Capitalisation Boursière

430.6M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

1.73M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $1.01Actuel $1.520Haut $3.45

Actualités Connexes

Analyst Upgrades

Raymond James Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $5

Raymond James analyst Laura Prendergast initiates coverage on Erasca with a Outperform rating and announces Price Target of $5.

Voir plus
Raymond James Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $5
GlobeNewswire

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors,

Voir plus
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
Analyst Upgrades

Goldman Sachs Maintains Buy on Erasca, Lowers Price Target to $3

Goldman Sachs analyst Chris Shibutani maintains Erasca with a Buy and lowers the price target from $3.5 to $3.

Voir plus
Goldman Sachs Maintains Buy on Erasca, Lowers Price Target to $3
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Erasca, Maintains $6 Price Target

HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca with a Buy and maintains $6 price target.

Voir plus
HC Wainwright & Co. Reiterates Buy on Erasca, Maintains $6 Price Target
Analyst Upgrades

Morgan Stanley Assumes Erasca at Overweight, Maintains Price Target of $4

Morgan Stanley analyst Jeffrey Hung assumes Erasca with a Overweight rating and maintains Price Target of $4.

Voir plus
Morgan Stanley Assumes Erasca at Overweight, Maintains Price Target of $4

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.